Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13.5Revenue (TTM) $M9.9Net Margin (%)-79.0Altman Z-Score-54.2
Enterprise Value $M12.6EPS (TTM) $-4.9Operating Margin %-78.2Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-79.0Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.4Cash flow > EarningsY
Price/Sales1.85-y EBITDA Growth Rate %-23.7Current Ratio0.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-587.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M2.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OPNT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

OPNT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


OPNT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.591.43view
Sinclair MichaelExecutive Chairman, 10% Owner 2015-01-15Sell1,700$3.591.43view
COHEN MARC AChairman,CEO,Treas, & Sec, 10% Owner 2012-06-14Sell243$2450-99.73view
KAISER RONALD WDirector 2012-06-06Sell100$2604-99.74view
KAISER RONALD WDirector 2010-12-08Sell100$2608-99.74view
Wesley Melvin IIICFO 2010-11-29Sell11$2424-99.72view
Wesley Melvin IIICFO 2010-11-18Sell23$2190-99.69view
COHEN ALAIN JPresident & Chief Tech Officer, 10% Owner 2010-07-27Sell2$1515-99.56view
COHEN MARC AChairman, CEO, Treas, & Sec, 10% Owner 2010-07-27Sell3$1515-99.56view
Wesley Melvin IIICFO 2010-07-27Sell1$1515-99.56view

Quarterly/Annual Reports about OPNT:

News about OPNT:

Articles On GuruFocus.com

More From Other Websites
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Nov 22 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: 2016 By the Numbers : November 22, 2016 Nov 22 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Nov 10 2016
Opiant Pharmaceuticals, Inc. Announces Appointment of Thomas T. Thomas to Board of Directors Nov 10 2016
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q4, 2016 By the Numbers : November 4, 2016 Nov 04 2016
OPIANT PHARMACEUTICALS, INC. Financials Nov 03 2016
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and... Oct 31 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Oct 28 2016
Opiant Pharmaceuticals, Inc. Licenses Heroin Vaccine From Walter Reed Army Institute of Research and... Oct 28 2016
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for Narcan® Nasal Spray Patent Oct 27 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Oct 25 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 06 2016
Opiant Pharmaceuticals, Inc.’s Partner, Adapt Pharma Limited, Announces NARCAN® Nasal Spray... Oct 05 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Sep 21 2016
Narcan Nasal Spray Inventor on U.S. Drug Epidemic Sep 15 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure Sep 13 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 08 2016
They Developed A Disruptive Drug With Government Funding And Trade Crazy Cheap Aug 15 2016
After $500 Million Exit, Pharma Experts Shift Focus To This Disruptive Company’s Product Jul 21 2016
OPIANT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Jun 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)